Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes Biotech

AstraZeneca Acquires EsoBiotec for $1 Billion to Strengthen Cell-Therapy Portfolio

by Team Lumida
March 17, 2025
in Biotech, Markets
Reading Time: 3 mins read
A A
0
vitamin b 12 100 mg

Photo by Mika Baumeister on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

Powered by lumidawealth.com

  • AstraZeneca will pay $425 million upfront, with an additional $575 million tied to milestones.
  • The acquisition includes EsoBiotec’s innovative in vivo cell therapy platform.
  • The deal is expected to close in Q2 2025 and will not impact AstraZeneca’s 2025 financial guidance.
  • This move positions AstraZeneca to expand its presence in the growing cell-therapy market.

What Happened?

AstraZeneca announced the acquisition of Belgian biotech company EsoBiotec in a deal valued at up to $1 billion. The British pharmaceutical giant will pay $425 million upon closing, expected in the second quarter of 2025, and up to $575 million in milestone payments. The acquisition includes EsoBiotec’s in vivo cell therapy platform, which modifies immune cells directly within the patient’s body, potentially improving accessibility and reducing treatment costs.

Why It Matters?

This acquisition underscores AstraZeneca’s strategic focus on expanding its cell-therapy portfolio, a rapidly growing area in biotechnology. The in vivo cell therapy platform offers a significant advantage by eliminating the need for complex manufacturing processes, which could lower costs and broaden patient access. For investors, this move highlights AstraZeneca’s commitment to innovation and its ability to compete in cutting-edge therapeutic areas, potentially driving long-term growth.

What’s Next?

The deal is expected to close in Q2 2025, with AstraZeneca focusing on integrating EsoBiotec’s technology into its pipeline. Investors should monitor the progress of regulatory approvals and milestone achievements, as these will determine the full financial impact of the acquisition. Additionally, AstraZeneca’s ability to commercialize this platform effectively will be a key factor in its success in the cell-therapy market.

Source
Previous Post

Nvidia Gains on Strong AI Demand Signals from Key Supplier Foxconn

Next Post

Nvidia’s AI Event Sparks Gains for Asian Suppliers as Next-Gen Chips Drive Market Optimism

Recommended For You

JPMorgan’s Jamie Dimon Warns of Bond Market Crisis Amid U.S. Fiscal Challenges

by Team Lumida
20 hours ago
Tax-Loss Harvesting Surge: JPMorgan’s $15 Billion Windfall

Key Takeaways: Powered by lumidawealth.com JPMorgan CEO Jamie Dimon predicts a “crack in the bond market” unless the U.S. addresses its spiraling national debt, which now exceeds $36 trillion....

Read more

Chinese Tech Stocks Slide as U.S.-China Trade Talks Stall

by Team Lumida
2 days ago
Chinese Stock Surge: A Hedge Fund Headache?

Key Takeaways: Powered by lumidawealth.com Chinese tech stocks fell sharply, with Alibaba down 4.2%, BYD dropping 3.8%, and Baidu losing 3.9%, as the Hang Seng Tech Index declined 2.7%....

Read more

Shell Acquires TotalEnergies’ Stake in Nigerian Oil Field for $510 Million

by Team Lumida
3 days ago
Shell Acquires TotalEnergies’ Stake in Nigerian Oil Field for $510 Million

Key Takeaways: Powered by lumidawealth.com Shell will purchase TotalEnergies’ 12.5% stake in Nigeria’s deep-water Bonga oil field for $510 million, increasing its ownership to 67.5%. The acquisition aligns with...

Read more

U.S. Halts Jet Engine Tech Exports to China, Threatening Comac’s C919 Program

by Team Lumida
3 days ago
U.S. Halts Jet Engine Tech Exports to China, Threatening Comac’s C919 Program

Key Takeaways: Powered by lumidawealth.com The U.S. has barred the export of critical jet engine parts and technology to China, targeting state-owned Commercial Aircraft Corp of China Ltd (Comac)....

Read more

Wall Street Turns to Hedges on Chinese Stocks Ahead of Tariff Deadline

by Team Lumida
4 days ago
close-up photo of monitor displaying graph

Key Takeaways: Powered by lumidawealth.com Chinese equities have rallied nearly 25% since April, but analysts warn of potential selloffs as the U.S.-China trade truce ends in August and geopolitical...

Read more

GM CEO Mary Barra Discusses EV Strategy Amid Tariffs and Shifting Consumer Demands

by Team Lumida
4 days ago
GM CEO Mary Barra Discusses EV Strategy Amid Tariffs and Shifting Consumer Demands

Key Takeaways: Powered by lumidawealth.com GM CEO Mary Barra envisions an “all-electric” future but acknowledges challenges such as rising costs, tariffs, and slowing EV sales. GM has redirected $888...

Read more

UniCredit to Double Stake in Greek Bank Alpha Services to 20%, Adding €180 Million in Annual Profit

by Team Lumida
4 days ago
UniCredit to Double Stake in Greek Bank Alpha Services to 20%, Adding €180 Million in Annual Profit

Key Takeaways: Powered by lumidawealth.com UniCredit plans to increase its stake in Greece’s Alpha Services from 9.6% to around 20% through financial instruments acquired at a discount to market...

Read more

Luxury Brands Face Fallout from Pandemic Price Hikes as Sales Decline

by Team Lumida
4 days ago
Luxury Brands Face Fallout from Pandemic Price Hikes as Sales Decline

Key Takeaways: Powered by lumidawealth.com Luxury brands that aggressively raised prices during the pandemic, such as Chanel and Dior, are now reporting disappointing sales and profit declines. Chanel’s sales...

Read more

Tesla’s European Sales Halve in April as Chinese Rivals Gain Ground

by Team Lumida
5 days ago
blue coupe parked beside white wall

Key Takeaways: Powered by lumidawealth.com Tesla’s new-car registrations in the EU fell nearly 53% in April, marking the fourth consecutive month of declining sales in the region. Chinese automakers...

Read more

Apple Suppliers in Asia Drop as Trump Threatens 25% Tariffs on iPhones

by Team Lumida
6 days ago
Can Apple’s Vision Pro Bounce Back with a Budget-Friendly Model?

Key Takeaways: Powered by lumidawealth.com Apple’s Asian suppliers, including AAC Technologies, TSMC, and Hon Hai Precision, saw declines after President Trump threatened a 25% tariff on all imported iPhones....

Read more
Next Post
Nvidia’s AI Demand Surge: Hon Hai Ramps Up Server Production

Nvidia’s AI Event Sparks Gains for Asian Suppliers as Next-Gen Chips Drive Market Optimism

China’s Economic Struggles: Factory Activity Falls Again

China Starts 2025 with Strong Economic Momentum Amid Rising U.S. Tariffs

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

A store filled with lots of different types of clothing

Economic Shifts: U.S. and China Consumers Tighten Their Wallets

August 5, 2024
China’s Financial Overhaul: Xi’s Strategy to Rebalance $9.1 Trillion Debt Crisis

China Pledges Policy Support to Counter U.S. Tariffs and Boost Domestic Growth

April 25, 2025
Powell’s Pivotal Moment: What to Expect from Jackson Hole

Wall Street Rallies on Rate-Cut Speculation: What Investors Need to Know

August 30, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018